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ABSTRACTS OF MEMBERS' PROFFERED PAPERS
MAINTENANCE OF HUMAN TU -
MOURS IN IMMUNE DEFICIENT
MICE. C. R. FRANKS, Imperial Cancer
Research Fund Breast Cancer Unit,
Guy's Hospital, London. F. T. PERKINS,
L. R. BOULGER and J. THORNTON HOLMES,
National Institute of Biological Standards
and Control.
In a preliminary study (Franks, Perkins
and Holmes, Nature, Lond., 1973, 243,
5402, 91) it was shown that human tumours
could be grown subcutaneously in thym-
ectomized, irradiated mice (900 rad), which
h-ad been reconstituted using 1 x 107 syn-
geneic bone marrow cells. This method
has justified its earlier promise, and tumour
survivals of 42 months have now been
experienced (Franks, Perkins and Holmes,
1974, Communication, Surgeons Sections,
Royal Society of Medicine).
The tumours were obtained at operation
from patients with primary cancer and
transported to the laboratory in Eagle's
MEM containing 2% calf serum, 200 u
penicillin, and 100 [kg ml-' streptomycin.
To date, 13 different histological types
have been studied. The growth of tumours
was initially assessed by direct palpation
and the histology confirmed by microscopical
examination. Metastatic growth was ob-
served at post-mortem examination in a
melanoma, and HeLa, rectal and colonic
tumour types.
INFLUENCE OF TRANSPLANTATION
SITE ON THE ESTABLISHMENT OF
HUMAN TUMOUR XENOGRAFTS IN
IMMUNOSUPPRESSED MICE. J. A.
DOUBLE and C. R. BALL, Department of
Experimental Pathology and Cancer Re-
search, University of Leeds.
We have transplanted a series of 42
human tumours in immunosuppressed CBA
mice (Davies et al., Transplantation, 1966, 4,
438). The take rate achieved has been
5/12 for colon tumours, 8/18 for rectum and
2/12 for bladder. Tumour fragments have
been transplanted either under the renal
capsule or subcutaneously, and a positive
" take " scored as a visible nodule at laparo-
tomy, or in subcutaneous transplants as a
palpable nodule, 8 weeks after transplanta-
tion.
Our results indicate that the transplanta-
tion site may be an important factor in
determining a " take " in this system. The
total success rate for colorectal tumours
(13/30, 430o) compares unfavourably with
smaller published series using similar tech-
niques (Castro, Nature, New Biol., 1972,
239, 83; Detre and Gazet, Br. J. Cancer,
1973, 28, 412). However, our success rate
(7/11, 64%) in renal capsule transplants is
significantly higher than in subcutaneous
ones (6/19, 31%). Subcutaneous tumours
arise in few animals of the transplanted
group, have a tendency to regress, and in
our hands are not transplantable. Renal
capsule tumours occur in the majority of
transplanted animals and further trans-
plantation (3/4 attempted) is frequently
possible. The reasons for these differences
are not apparent at present.
IMMUNIZATION AGAINST MAREK'S
DISEASE USING VIRUS SPECIFIC
ANTIGENS FREE FROM INFECTIOUS
VIRUS. F. LESNIK and L. J. N. Ross,
Houghton Poultry Research Station, Hunt-
ingdon.
Previous studies have established that
immunization against Marek's disease (MD)
can be achieved using live attenuated viruses
serologically related to Marek's disease
virus (MDV). However, the role of viral
antigens in immunity is unknown.
We have shown in this study that im-
munity can be conferred in the absence
of vaccine virus replication using detergent
soluble antigens extracted from cells infected
with attenuated MDV. Extracts were cent-
rifuged at 100,000 g for 2 h and both sedi-
mentable and non-sedimentable (soluble)
materials were used to immunize MD
susceptible chickens. These were inoculated
i.m. at 7 days of age with antigens emulsified
in Freund's complete adjuvant and were
given a second inoculation without adjuvant
after 10 days. When compared with con-
trols it was noted that immunization with
soluble antigens extracted with the non-ionic
detergent NP40 reduced mortality from
910% to 350o (P < 0 01) during a period
of 19 weeks following exposure to MD. A
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by immunization wNNith sedimentable materials
inactivated with formalin. Further data
will be presented on the effect of immuniza-
tion on other parameters of infection such
as viraemia and changes in antibody titres
during the course of the disease.
SURFACE IMMUNOLOGICAL MARK-
ERS IN ACUTE MYELOBLASTIC LEU-
KAEMIA. G. M. TAYLOR, C. B. FREEMAN,
J. ESCUDER and R. HARRIS, Department of
Medical Genetics, St Mary's Hospital, Man-
chester.
Before treatment, peripheral blood leuco-
cytes from patients with acute myeloblastic
leukaemia (AML) form few T and B cell
rosettes compared with normal individuals,
and AML blasts do not themselves form
rosettes, unlike a minority of cases of acute
lymphoblastic leukaemia in which T rosette
forming cells are known to occur. A large
but variable proportion of peripheral leuco-
cytes from patients with untreated AML
possess surface immunoglobulin detected by
both direct and indirect immunofluorescence.
The pattern of fluorescent staining on
AML blasts differs from that seen on CLL
cells, and also in contrast in vitro with anti-
human immunoglobulin serum. Surface im-
munoglobulin on AML blasts may represent
tumour associated antibody or immune
complex.
Our results suggest that the proportion
of rosette forming cells, and of cells with
surface immunoglobulin can be used as a
diagnostic aid for patients with AML.
TISSUE CULTURE OF MALIGNANT
EFFUSIONS AND THEIR USEFUL-
NESS AS TARGET CELLS IN CYTO-
TOXICITY CELLS. R. H. WHITEHEAD,
University Department of Surgery, Welsh
National School of Medicine, Cardiff.
Breast tumours pose special problems for
those seeking to study the immune respon-
siveness of patients to their tumours. It is
difficult, if not impossible, to culture breast
cancer cells itn vitro. This has led previous
workers studying lymphocyte cytotoxicity
to use cells derived from effusions from
patient,s Mwithl advanced breast cancer. This
wN-as donie )ecause of thle belief that pleuri:al
effusion cells were free of fibroblasts and
were most probably tumour cells.
Comparative cytotoxicity tests have been
performed using cells derived from pleural
effusions from breast cancer patients and
cells derived from ascites from colon car-
cinoma patients. Cells derived from a
malignant melanoma have also been used
as target cells. Lymphocytes from patients
with breast cancer, colon cancer and melan-
oma have been tested against their cells.
These tests failed to show any tumour
specific cytotoxicity (except in the case of
melanoma), suggesting that the cells derived
from these effusions are ofnormal origin.
CELL MEDIATED IMMUNOREACTI-
VITY IN HUMAN LUNG NEOPLASIA.
B. M. VOSE and M. MOORE, Immunology
Department, Paterson Laboratories, Man-
chester.
The relative susceptibilities of various
tissue culture cells derived principally from
malignant, normal and foetal lung tissues,
to cytolysis by leucocytes from patients with
different histological types of lung cancer
were investigated using an in vitro micro-
cytotoxicity assay for cell mediated im-
munity.
Target cells derived from 12- to 17-week
old embryo lungs and from pulmonary
tumours of different histological types were
most susceptible to the cytotoxic action of
lung cancer patients' leucocytes, while a
lower but significant frequency of positive
reactions has also been observed against
cells originating from non-malignant pul-
monary tissue.
It is concluded that lung tumour cells
may express tumour associated antigens
but their nature and specificity remain to
be elucidated.
AN ATTEMPT TO IDENTIFY STIMU-
LATORY SUBSTANCES INTERFER-
ING WITH A TWO STAGE MACRO-
PHAGE MIGRATION INHIBITION
(MMI) ASSAY AND TO ASSESS IM-
MUNOCOMPETENCE. J. G. AASKOV
and H. M. ANTHONY, Department of Ex-
perimental Pathology and Cancer Researchl,
University of Leeds.
An iInlprove(l two-stage MIA11 test lhas
b)eeli developed to ineasure the primiary
19